Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

PRIMARY OBJECTIVE(S): I. To determine the safety of gruticibart as measured by the incidence of CRT in individuals with a CVC II. To determine the efficacy of gruticibart as measured by the incidence of CRT in individuals with a CVC II. To determine the efficacy of gruticibart as measured by the incidence of CRT in individuals with a CVC SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of gruticibart in patients with a CVC II. To determine the efficacy of gruticibart as measured by the time to CRT and incidence of any thrombosis in individuals with a CVC OUTLINE: Participants are randomized to 1 of 2 arms. Arm A. Participants receive single dose of placebo IV via CVC or peripheral IV line. Arm B. Participantsreceive single dose of gruticibart (2 mg/kg) IV via CVC or peripheral IV line. After completion of study treatment, participants will be followed for AEs for a total of 30 days from time of administration of study drug, and are considered off-study after 30 days. .